AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35871930 — intervention group
Group type: COMPARATOR
Intervention: Standard 6-month bridging with IB (historic control)
Number of subjects: 26
Study 35872072 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Enterography (MRE) based index (PICMI)
Number of subjects: 159
Study 35872137 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular diastolic function parameters (e', E/e', LV mass index)
Number of subjects: 2082
Study 35872137 — intervention group
Group type: EXPERIMENTAL
Intervention: Categorical classification of left ventricular diastolic dysfunction (LVDD)
Number of subjects: 2082
Study 35872377 — intervention group
Group type: COMPARATOR
Intervention: Medium-dose BDP/FF/G
Number of subjects: 0
Study 35872377 — intervention group
Group type: COMPARATOR
Intervention: High-dose BDP/FF/G
Number of subjects: 0
Study 35872509 — intervention group
Group type: EXPERIMENTAL
Intervention: Epigenetic gene alterations (EGA) identified through whole exome sequencing (WES) in patients with metastatic solid tumours.
Number of subjects: 292
Study 35872509 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of epigenetic gene alterations (EGA)
Number of subjects: 292
Study 35872509 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-occurrence of EGA with driver gene alteration
Number of subjects: 292
Study 35872563 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's Depression Scale
Number of subjects: 31
Study 35872563 — intervention group
Group type: EXPERIMENTAL
Intervention: Walter Reed Visual Assessment Scale
Number of subjects: 31
Study 35872563 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobb method (scoliosis severity)
Number of subjects: 31
Study 35872563 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior trunk rotation
Number of subjects: 31
Study 35872644 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-Care (POC) VL testing using Cepheid Xpert
Number of subjects: 541
Study 35872644 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-Care (POC) VL testing
Number of subjects: 541
Study 35872644 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-Care (SOC) VL testing
Number of subjects: 541
Study 35872693 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 pandemic
Number of subjects: 31
Study 35872777 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil or mycophenolic acid (MMF/MPA)
Number of subjects: 132
Study 35872777 — intervention group
Group type: COMPARATOR
Intervention: No MMF/MPA
Number of subjects: 132
Study 35872799 — intervention group
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Number of subjects: 62
Study 35872799 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol
Number of subjects: 62
Study 35873000 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (Tofa) 5 mg twice a day
Number of subjects: 9
Study 35873000 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (Tofa) at 200, 400, or 800 nM
Number of subjects: 9
Study 35873000 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (Tofa)
Number of subjects: 9
Study 35873000 — intervention group
Group type: COMPARATOR
Intervention: TNFα
Number of subjects: 9
Study 35873264 — intervention group
Group type: EXPERIMENTAL
Intervention: Real cTBS and real SCRT
Number of subjects: 72
Study 35873264 — intervention group
Group type: COMPARATOR
Intervention: Sham cTBS and real SCRT
Number of subjects: 72
Study 35873264 — intervention group
Group type: COMPARATOR
Intervention: Sham SCRT
Number of subjects: 72
Study 35873264 — intervention group
Group type: COMPARATOR
Intervention: No interventions (age- and gender-matched controls)
Number of subjects: 72
Study 35873364 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored web-based EF intervention
Number of subjects: 0
Study 35873420 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula with 1.5 g/L HMOs (test group 1, TG1)
Number of subjects: 0
Study 35873420 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant formula with 2.5 g/L HMOs (test group 2, TG2)
Number of subjects: 0
Study 35873420 — intervention group
Group type: COMPARATOR
Intervention: Standard cow's milk-based infant formula (control group, CG)
Number of subjects: 0
Study 35873420 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk-fed group (HMG)
Number of subjects: 0
Study 35873652 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage radiotherapy (SRT) with 70 Gy in 35 fractions, adapted after 50 Gy, with sequential lymph node irradiation for non-responders.
Number of subjects: 100
Study 35873652 — intervention group
Group type: EXPERIMENTAL
Intervention: PSMA-PET imaging at baseline and treatment planning consideration for non-responders after 50 Gy.
Number of subjects: 100
Study 35873652 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes regarding side effects.
Number of subjects: 100
Study 35873764 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative personalized intervention using EEG-based brain-computer interface, multi-channel functional electrical stimulation, and hand exoskeleton for upper-limb rehabilitation.
Number of subjects: 30
Study 35873764 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of non-invasive brain stimulation (anodal transcranial direct current stimulation) to the initial approach in the second phase of the intervention.
Number of subjects: 30
Study 35874156 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing Duration of rTMS treatment
Number of subjects: 0
Study 35874156 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing Intensity of rTMS treatment
Number of subjects: 0
Study 35874156 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing Duration and Intensity of rTMS treatment
Number of subjects: 0
Study 35874466 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutralizing anti-Tim-3 antibodies
Number of subjects: 98
Study 35874466 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutralizing anti-PD-1 antibodies
Number of subjects: 98
Study 35874466 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble Tim-3 levels
Number of subjects: 98
Study 35874558 — intervention group
Group type: EXPERIMENTAL
Intervention: Full ADBB scale
Number of subjects: 145
Study 35874558 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ADBB scale
Number of subjects: 145
Study 35874558 — intervention group
Group type: EXPERIMENTAL
Intervention: Both scales
Number of subjects: 145
Study 35874564 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine at 0.2 μg/kg/min
Number of subjects: 14
Study 35875477 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga-based program
Number of subjects: 256
Study 35875477 — intervention group
Group type: COMPARATOR
Intervention: Structured exercise program (SEP)
Number of subjects: 256
Study 35875816 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted drugs based on druggable ctDNA alterations identified by next-generation sequencing (NGS)
Number of subjects: 223
Study 35875816 — intervention group
Group type: COMPARATOR
Intervention: Physician-chosen treatment for patients without druggable ctDNA alterations
Number of subjects: 223
Study 35875815 — intervention group
Group type: EXPERIMENTAL
Intervention: PCS severity score developed in sub-cohort Kiel-I based on 12 long-term symptom complexes.
Number of subjects: 0
Study 35875815 — intervention group
Group type: EXPERIMENTAL
Intervention: PCS score replication and identification of clinically meaningful predictors in validation sub-cohorts (Würzburg/Berlin, Kiel-II).
Number of subjects: 0
Study 35875853 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECISE-DAPT score at baseline
Number of subjects: 480
Study 35875853 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECISE-DAPT score reassessed during follow-up
Number of subjects: 480
Study 35875853 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECISE-DAPT score at follow-up
Number of subjects: 480
Study 35876084 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 0
Study 35876084 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental care adaptation for obese individuals
Number of subjects: 0
Study 35876120 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month multicomponent training (MCT)
Number of subjects: 102
Study 35876120 — intervention group
Group type: COMPARATOR
Intervention: Usual lifestyle (Control group)
Number of subjects: 102
Study 35876145 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed meal times (8:00 am, 1:00 pm, 6:00 pm)
Number of subjects: 36
Study 35876145 — intervention group
Group type: EXPERIMENTAL
Intervention: Everyday life conditions
Number of subjects: 36
Study 35876145 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed meal times
Number of subjects: 36
Study 35876164 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal NK cells from congenitally CMV infected newborns
Number of subjects: 0
Study 35876164 — intervention group
Group type: COMPARATOR
Intervention: Uninfected controls
Number of subjects: 0
Study 35876255 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35876391 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC with increased Let-7a
Number of subjects: 120
Study 35876391 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC with decreased miR-145
Number of subjects: 120
Study 35876391 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC with reduced Let-7a
Number of subjects: 120
Study 35876391 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC with reduced miR-145
Number of subjects: 120
Study 35876408 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary flow reserve (CFR) measurement
Number of subjects: 1889
Study 35876408 — intervention group
Group type: EXPERIMENTAL
Intervention: Target vessel failure (composite of cardiac death, target vessel myocardial infarction, or clinically driven target vessel revascularization)
Number of subjects: 1889
Study 35876418 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation treatment
Number of subjects: 0
Study 35876452 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Talk Intervention (FTI)
Number of subjects: 20
Study 35876473 — intervention group
Group type: EXPERIMENTAL
Intervention: External anal sphincter (EAS) muscle function assessment
Number of subjects: 199
Study 35876473 — intervention group
Group type: EXPERIMENTAL
Intervention: Puborectal muscle (PRM) function assessment
Number of subjects: 199
Study 35876473 — intervention group
Group type: EXPERIMENTAL
Intervention: Association between muscle function and number of PFS
Number of subjects: 199
Study 35876473 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of PFS
Number of subjects: 199
Study 35876634 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density surface electromyography (HD-sEMG)
Number of subjects: 91
Study 35876634 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 91
Study 35876634 — intervention group
Group type: COMPARATOR
Intervention: Current methods for muscle evaluation (including DXA, handgrip strength, and physical performance)
Number of subjects: 91
Study 35876637 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall diet quality score (max score 30)
Number of subjects: 7736
Study 35876637 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fat score (max score 18)
Number of subjects: 7736
Study 35876637 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet quality scores by GBD region
Number of subjects: 7736
Study 35876637 — intervention group
Group type: EXPERIMENTAL
Intervention: Atherosclerotic cardiovascular risk scores
Number of subjects: 7736
Study 35876646 — intervention group
Group type: COMPARATOR
Intervention: No prior vascular disease
Number of subjects: 37198
Study 35876646 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-territory vascular disease
Number of subjects: 37198
Study 35876646 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisite artery disease
Number of subjects: 37198
Study 35876660 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycemia (blood glucose level <3.0 mmol/L)
Number of subjects: 94
Study 35876678 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct brainstem stimulation at 2 mA
Number of subjects: 30
Study 35876678 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct brainstem stimulation at 1 mA
Number of subjects: 30
Study 35876678 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sensitivity and specificity for the association of stimulation intensity and DS-to-T
Number of subjects: 30
Study 35876678 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative evaluation using modified Ranking Scale and motor function
Number of subjects: 30
Study 35876699 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of CCL19 and CCL21
Number of subjects: 414
Study 35876699 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of CCL21 at admission
Number of subjects: 414
Study 35876706 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 by Moderna
Number of subjects: 0
Study 35876706 — intervention group
Group type: COMPARATOR
Intervention: BNT162b2 by Pfizer-BioNTech
Number of subjects: 0
Study 35876706 — intervention group
Group type: EXPERIMENTAL
Intervention: Preinfection with SARS-CoV-2
Number of subjects: 0
Study 35876706 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 0
Study 35876706 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly PWH and those with low CD4+ cell count
Number of subjects: 0
Study 35876829 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet agents plus best medical practice (BMP)
Number of subjects: 1625
Study 35876829 — intervention group
Group type: COMPARATOR
Intervention: BMP alone
Number of subjects: 1625
Study 35876829 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet agents plus BMP
Number of subjects: 1625
Study 35876960 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D convolutional neural network (CNN) using functional MRI data
Number of subjects: 29
Study 35876960 — intervention group
Group type: EXPERIMENTAL
Intervention: Majority voting strategy with 3D CNN
Number of subjects: 29
Study 35876960 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxel-wise visualization method based on convolutional filters
Number of subjects: 29
Study 35876960 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional MRI traits analysis of misclassified patients
Number of subjects: 29
Study 35876974 — intervention group
Group type: EXPERIMENTAL
Intervention: D-Pd (Daratumumab, Pomalidomide, Dexamethasone)
Number of subjects: 479
Study 35876974 — intervention group
Group type: COMPARATOR
Intervention: D-Vd (Daratumumab, Bortezomib, Dexamethasone)
Number of subjects: 479
Study 35876974 — intervention group
Group type: COMPARATOR
Intervention: Vd (Bortezomib, Dexamethasone)
Number of subjects: 479
Study 35877061 — intervention group
Group type: EXPERIMENTAL
Intervention: Collateral-core ratio (CCR)
Number of subjects: 129
Study 35877061 — intervention group
Group type: COMPARATOR
Intervention: Prediction model without CCR
Number of subjects: 129
Study 35877070 — intervention group
Group type: EXPERIMENTAL
Intervention: ECV ≥ 30%
Number of subjects: 703
Study 35877070 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-stratification model based on LGE, LVEF ≤ 35%, and ECV ≥ 30%
Number of subjects: 703
Study 35877070 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive CMR evaluation
Number of subjects: 703
Study 35877091 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICI)
Number of subjects: 386
Study 35877091 — intervention group
Group type: COMPARATOR
Intervention: Platinum-based chemotherapy
Number of subjects: 386
Study 35877173 — intervention group
Group type: EXPERIMENTAL
Intervention: Omacor (omega-3 polyunsaturated fatty acids)
Number of subjects: 2167
Study 35877173 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital reporting of adherence
Number of subjects: 2167
Study 35877173 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-based enquiry
Number of subjects: 2167
Study 35877173 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life data from digitally engaged patients
Number of subjects: 2167
Study 35877269 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 298
Study 35877687 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical criteria for stratifying risk of injuries to the abdomen and pelvis among adult blunt trauma patients.
Number of subjects: 6340
Study 35877687 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision instrument based on clinical criteria.
Number of subjects: 6340
Study 35877687 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of the decision rule among a new cohort of patients in Phase 2.
Number of subjects: 6340
Study 35877767 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS stimulation of blood leukocytes
Number of subjects: 77
Study 35877767 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma concentrations of host response biomarkers
Number of subjects: 77
Study 35878076 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses
Number of subjects: 24343
Study 35878076 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses in high-risk settings
Number of subjects: 24343
Study 35878076 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses in low-risk settings
Number of subjects: 24343
Study 35878076 — intervention group
Group type: EXPERIMENTAL
Intervention: Black or Hispanic nurses
Number of subjects: 24343
Study 35878076 — intervention group
Group type: COMPARATOR
Intervention: Nonnurse HCWs
Number of subjects: 24343
Study 35878569 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation Program (PRP) for 4 weeks
Number of subjects: 80
Study 35878640 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear Osia 2 System
Number of subjects: 29
Study 35878676 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant drugs (AD) treatment for 6 months
Number of subjects: 377
Study 35878714 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant stereotactic body radiotherapy (SBRT) at 30-35 Gy/5 fractions to the prostate and seminal vesicles, and 25 Gy/5 fractions to the pelvic lymph nodes.
Number of subjects: 16
Study 35878714 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant stereotactic body radiotherapy (SBRT) followed by radical prostatectomy (RP).
Number of subjects: 16
Study 35878714 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant SBRT followed by RP.
Number of subjects: 16
Study 35878737 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35878742 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic cGVHD diagnosed based on NIH Consensus Criteria (NCC)
Number of subjects: 302
Study 35878742 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal liver tests (ALT, AST, ALP, GGT)
Number of subjects: 302
Study 35878742 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic features of GVHD
Number of subjects: 302
Study 35878742 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cholesterol >220 mg/dL
Number of subjects: 302
Study 35878742 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine profiles
Number of subjects: 302
Study 35878742 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased platelet count
Number of subjects: 302
Study 35878932 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized 6-month walking exercise program at home
Number of subjects: 227
Study 35878932 — intervention group
Group type: EXPERIMENTAL
Intervention: High adherence subgroup (>60% of prescribed sessions) to the walking exercise program
Number of subjects: 227
Study 35878932 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian analysis of the exercise program
Number of subjects: 227
Study 35878932 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analyses restricted to hospitalization risk
Number of subjects: 227
Study 35879039 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Number of subjects: 700
Study 35879127 — intervention group
Group type: EXPERIMENTAL
Intervention: PSMA-RGS
Number of subjects: 18
Study 35879335 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet (GFD)
Number of subjects: 12981
Study 35879678 — intervention group
Group type: EXPERIMENTAL
Intervention: ASSIST 1.0
Number of subjects: 17
Study 35879678 — intervention group
Group type: COMPARATOR
Intervention: Regular home care (control)
Number of subjects: 17
Study 35879765 — intervention group
Group type: EXPERIMENTAL
Intervention: AKI defined by serum creatinine (sCr)
Number of subjects: 1286
Study 35879765 — intervention group
Group type: EXPERIMENTAL
Intervention: AKI defined by urine output (UO)
Number of subjects: 1286
Study 35879765 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent AKI
Number of subjects: 1286
Study 35879765 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute kidney disease (AKD)
Number of subjects: 1286
Study 35879765 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid reversal of AKI
Number of subjects: 1286
Study 35879765 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney recovery in surviving AKI patients
Number of subjects: 1286
Study 35879931 — intervention group
Group type: EXPERIMENTAL
Intervention: valoctocogene roxaparvovec (AAV5-hFVIII-SQ) infusion
Number of subjects: 23
Study 35879962 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation ablation
Number of subjects: 650
Study 35880164 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) regimen delivering 30 Gy in five planned consecutive daily fractions.
Number of subjects: 23
Study 35880474 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 4805
Study 35880474 — intervention group
Group type: COMPARATOR
Intervention: Control (Q1-Q3; NT-proBNP: Q1, ≤1556 pg/mL; Q2, >1556-2816 pg/mL; Q3, >2816-5314 pg/mL)
Number of subjects: 4805
Study 35880941 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive cell therapies
Number of subjects: 0
Study 35880940 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive cell therapy (including tumor-infiltrating lymphocyte therapy, engineered T cell receptor therapy, chimeric antigen receptor therapy, dendritic cell therapy, and natural killer cell therapy)
Number of subjects: 0
Study 35880942 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive cellular therapy (ACT)
Number of subjects: 0
Study 35880942 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor-infiltrating lymphocytes
Number of subjects: 0
Study 35880983 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin quantification on contrast-enhanced photon-counting CT data sets
Number of subjects: 0